Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 4/2015

01.12.2015 | Geriatric Bladder Dysfunction (GM Ghoniem, Section Editor)

Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly

verfasst von: Bilal Farhan, Gamal Ghoniem

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Overactive bladder (OAB) is a syndrome of urinary urgency, usually accompanied by frequency, nocturia, and sometimes urinary urgency incontinence. There are many guidelines for the OAB treatment which are constructed on a stepwise fashion starting from the least invasive to the more invasive therapy. The emergence of third-line therapy (AUA/SUFU guidelines) has resulted in significant decrease of more invasive surgery and improved patients’ quality of life. The aim of a clinical pathway is to improve the quality of care, reduce risks, increase patient satisfaction, and increase the efficiency in the use of resources. The available options for the third-line OAB treatments include intravesical injection of botulinum toxin A, percutaneous tibial nerve stimulation (PTNS), and sacral nerve stimulation (SNS). The available evidence confirms that all three treatment approaches are well tolerated and effective, although only botulinum toxin type A (BoNTA) and SNS can achieve nearly a cure of urgency urinary incontinence (UUI). The choice among the different third-line treatment depends on patient preference, availability, and local expertise. The application of these pathways can improve incontinence care by letting physicians adequately communicate with patients and select individualized therapy at an early stage especially for elderly patients.
Literatur
1.
Haylen BT et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMed
2.
Haab F. Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn. 2014;33 Suppl 3:S2–5.CrossRefPubMed
3.
Schurch B, Carda S. OnabotulinumtoxinA and multiple sclerosis. Ann Phys Rehabil Med. 2014;57(5):302–14.CrossRefPubMed
4.
Malde S et al. Patient experience and satisfaction with onabotulinumtoxin A for refractory overactive bladder. BJU Int. 2015;116(3):443–9.CrossRefPubMed
5.
6.
Stewart WF et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMed
7.
Sicras-Mainar A et al. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. BMC Urol. 2013;13:51.PubMedCentralCrossRefPubMed
8.
Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol. 2002;4 Suppl 4:S38–43.PubMedCentralPubMed
9.
Novara G et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol. 2010;58(2):218–38.CrossRefPubMed
10.••
Gormley EA et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. This is good article which considered as updated amendmnet guidelines for the diagnosis and treatment of OAB in AUA/SUFU.
11.
Nambiar A, Lucas M. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Neurourol Urodyn. 2014;33 Suppl 3:S21–5.CrossRefPubMed
12.
Hermieu JF et al. Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management: translation of French recommendations. Prog Urol. 2014;24(11):e1–7.CrossRefPubMed
13.
Sicras-Mainar A et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J. 2014;25(4):485–92.CrossRefPubMed
14.•
Elwyn G et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–7. This is the main point in the treatment of any disease in general and OAB in specific.  The decision to share with the patient and address “what matters most”, is the main key in the choice of treatment.
15.
Kelleher CJ et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104(9):988–93.CrossRefPubMed
16.
Schabert VF et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–22.PubMed
17.
Jundt K et al. Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet. 2011;284(3):663–6.CrossRefPubMed
18.
19.
Anger JT et al. Women’s experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups. Neurourol Urodyn. 2011;30(7):1295–9.PubMedCentralPubMed
20.
Amarenco G, Deffieux X. How to define refractory overactive bladder? Prog Urol. 2014;24(4):213–4.CrossRefPubMed
21.
Nitti VW et al. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn. 2010;29(4):652–7.CrossRefPubMed
22.
Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology. 2006;68(2 Suppl):29–37.CrossRefPubMed
23.
Schwantes U, Grosse J, Wiedemann A. Refractory overactive bladder: a common problem? Int Urogynecol J. 2015.
24.
Appell RA et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76(4):358–63.CrossRefPubMed
25.
Van Kerrebroeck P et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–21.CrossRefPubMed
26.
Knuepfer S, Juenemann KP. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol. 2014;6(1):34–42.PubMedCentralCrossRefPubMed
27.
Dolly JO, Lawrence GW. Chapter 3: molecular basis for the therapeutic effectiveness of botulinum neurotoxin type a. Neurourol Urodyn. 2014;33 Suppl 3:S14–20.CrossRefPubMed
28.
Cruz F, Nitti V. Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn. 2014;33 Suppl 3:S26–31.CrossRefPubMed
29.•
Tincello DG, Rashid T, Revicky V. Emerging treatments for overactive bladder: clinical potential of botulinum toxins. Res Rep Urol. 2014;6:51–7. This reviews good safety, durability, and cost for Botox in OAB.
30.
Chapple C et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.CrossRefPubMed
31.
Mohee A et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–13.CrossRefPubMed
32.
Fowler CJ et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57.CrossRefPubMed
33.
Chughtai B et al. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014;21(2):7217–21.PubMed
34.
Chancellor MB et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon. 2013;67:129–40.CrossRefPubMed
35.
National Collaborating Centre for Women’s. and Children’s Health. National Institute for Health and Clinical Excellence: guidance, in urinary incontinence in women: the management of urinary incontinence in women. London: Royal College of Obstetricians and Gynaecologists (UK) Copyright (c) 2013 National Collaborating Centre for Women's and Children's Health; 2013.
36.
Hamid R et al. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX((R))) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. Pharmacoeconomics. 2015;33(4):381–93.PubMedCentralCrossRefPubMed
37.
Anger JT et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol. 2010;183(6):2258–64.PubMedCentralCrossRefPubMed
38.
Nitti VW et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.CrossRefPubMed
39.
Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–10.CrossRefPubMed
40.
Schurch B et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol. 2000;164(3 Pt 1):692–7.CrossRefPubMed
41.
Harper M et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. 2003;92(3):325–6.CrossRefPubMed
42.
Cohen BL et al. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol. 2007;177(3):1006–10. discussion 1010.CrossRefPubMed
43.
Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19(7):880–2.CrossRefPubMed
44.
45.
Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn. 2008;27(1):28–33.CrossRefPubMed
46.
Primus G, Kramer G. Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence. Neurourol Urodyn. 1996;15(3):187–94.CrossRefPubMed
47.
Kessler TM et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74.CrossRefPubMed
48.
Lay AH, Das AK. The role of neuromodulation in patients with neurogenic overactive bladder. Curr Urol Rep. 2012;13(5):343–7.CrossRefPubMed
49.
Ohlsson BL. Effects of some different pulse parameters on the perception of intravaginal and intra-anal electrical stimulation. Med Biol Eng Comput. 1988;26(5):503–8.CrossRefPubMed
50.
Laudano MA et al. Disparities in the use of sacral neuromodulation among Medicare beneficiaries. J Urol. 2015;194(2):449–53.CrossRefPubMed
51.
Reynolds WS, Bales GT. Re: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. P. E. van Kerrebroeck, A. C. van Voskuilen, J. P. Heesakkers, A. A. Lycklama a Nijholt, S. Siegel, U. Jonas, C. J. Fowler, M. Fall, J. B. Gajewski, M. M. Hassouna, F. Cappellano, M. M. Elhilali, D. F. Milam, A. K. Das, H. E. Dijkema and U. van den Hombergh. J Urol 2007; 178: 2029-2034. J Urol. 2008;179(6):2483–4. author reply 2484.CrossRefPubMed
52.
Janknegt RA, Weil EH, Eerdmans PH. Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant. Urology. 1997;49(3):358–62.CrossRefPubMed
53.
Spinelli M et al. New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol. 2003;170(5):1905–7.CrossRefPubMed
54.
Kessler TM et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357–63.CrossRefPubMed
55.•
Al-Shaiji TF, Banakhar M, Hassouna MM. Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms. Adv Urol. 2011;2011:757454. This paper provides a review on the indications, possible mechanisms of action, surgical aspects and possible complications, and safety issues of the SNM & PTNS. The efficacy of the technique is also addressed.
56.
Nuhoglu B et al. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(3):204–7.CrossRefPubMed
57.
Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. Eur Urol. 1999;36(2):81–91.CrossRefPubMed
58.
Nakamura M et al. Bladder inhibition by electrical stimulation of the perianal skin. Urol Int. 1986;41(1):62–3.CrossRefPubMed
59.
Klingler HC et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000;56(5):766–71.CrossRefPubMed
60.
MacDiarmid SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40.CrossRefPubMed
61.
Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.CrossRefPubMed
62.
Karademir K et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Scand J Urol Nephrol. 2005;39(3):230–3.CrossRefPubMed
63.••
Gaziev G et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61. Good systemic review: four RCT for OAB which showed Level 1 evidence of efficacy for PTNS.
64.
Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.CrossRefPubMed
65.
Peters KM et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.CrossRefPubMed
Metadaten
Titel
Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly
verfasst von
Bilal Farhan
Gamal Ghoniem
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2015
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-015-0341-4

Weitere Artikel der Ausgabe 4/2015

Current Bladder Dysfunction Reports 4/2015 Zur Ausgabe

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Voiding Function in Women with Orthotopic Neobladders

Neurogenic Bladder (CR Powell, Section Editor)

Sacral Neuromodulation in Children

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Robotic Surgical Approaches to Bladder Reconstruction in Adults

Neurogenic Bladder (CR Powell, Section Editor)

Urinary Biomarkers Under Investigation for Overactive Bladder Syndrome

Geriatric Bladder Dysfunction (GM Ghoniem, Section Editor)

Urinary Diversion in the Elderly

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Evaluation and Management of Failed Bladder Reconstructions

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise